Navigation Links
Imprint of chemotherapy linked to inflammation in breast cancer survivors
Date:3/4/2014

Many breast cancer survivors experience fatigue and other debilitating symptoms that persist months to years after their course of treatment has ended.

Now researchers at the Winship Cancer Institute of Emory University have found clues that may explain how these symptoms can linger. Chemotherapy, one of the major treatments for breast cancer, can leave a long-lasting epigenetic imprint in the DNA of breast cancer patients' blood cells. That imprint is associated with biological signs of inflammation up to six months after the completion of treatment. Inflammation in turn is believed to cause symptoms like fatigue.

The findings are now published online in the journal Brain, Behavior and Immunity.

"Chemotherapy is a life-saving intervention, but for some women it comes at a cost," says Mylin Torres, MD, assistant professor of radiation oncology at Emory University School of Medicine and Winship Cancer Institute. "These results are the first to suggest a biological mechanism by which treatment-related side effects can persist long after treatment completion in women with breast cancer."

That achy, tired feeling that comes from the flu is caused by inflammation, the body's natural response to infection or a wound but it usually disappears once an illness is over. In patients being treated for cancer, fatigue has also been linked to inflammation and up to 30 percent of breast cancer survivors experience persistent fatigue long after treatment has ended.

To investigate the biology behind persistent cancer-related inflammation, Torres teamed up with Andrew Miller, MD, professor of psychiatry and behavioral sciences and director of psychiatric oncology at Winship Cancer Institute. First co-authors of the paper are Alicia Smith, PhD, assistant professor of psychiatry and behavioral sciences, and Karen Conneely, PhD, assistant professor of human genetics.

In a previously published study led by Torres and Miller, chemotherapy was associated with increased markers of inflammation in the blood which correlated with fatigue.

"We had found that increased fatigue was similar no matter whether patients received chemotherapy before or after surgery," Torres says, "indicating that the timing of chemotherapy was less important than whether you got it in the first place."

In the current study, all the women went through partial mastectomy surgery. Some received varying forms of chemotherapy, and all received radiation at the end. They found that women who had been treated with chemotherapy exhibited changes in the methylation of the DNA in their white blood cells. Some of these changes were still present six months after radiation.

Methylation is an epigenetic alteration in DNA, which does not change the A/C/G/T "letter" information in the DNA but does change how that information is read by the cell, influencing whether a gene is turned on or off.

The researchers scanned hundreds of thousands of potential sites of methylation; only eight sites were reliably altered in women who received chemotherapy, and changes at half of those sites were visible six months later.

The biology connecting this handful of sites to inflammation remains unclear; the eight sites were not in genes that encode inflammatory signaling proteins secreted into the blood, for example. However, the methylation changes did correlate with increased levels of two inflammatory signaling proteins, IL-6 and sTNFR2, that have been associated with fatigue in breast cancer survivors.

Many chemotherapeutic agents are effective precisely because they damage DNA in cancer cells. While it was well known that chemotherapy induces epigenetic changes in cancer cells, this is the first study to identify epigenetic changes induced by chemotherapy in non-cancerous cells of the blood.

The authors hypothesize that chemotherapy may directly alter methylation status in the blood cells, or it may be a result of the inflammatory response to chemotherapy-related tissue injury.

"It may be something about the intensity or the repetitive nature of chemotherapy that makes it qualitatively different from acute inflammation," Miller says. "The more we know about this imprinting process, the better chance we have of getting to new therapies for chronic treatment-related problems, such as fatigue, in breast cancer survivors."


'/>"/>
Contact: Quinn Eastman
qeastma@emory.edu
404-727-7829
Emory Health Sciences
Source:Eurekalert

Related medicine news :

1. Study identifies protein that helps developing germ cells wipe genes clean of past imprints
2. Chemotherapy proves life-saving for some leukemia patients who fail induction therapy
3. Adding drug to standard chemotherapy provides no survival benefit for older lung cancer patients
4. Genetic predictor of breast cancer response to chemotherapy
5. Chemotherapys effect on overall survival seems to increase based on tumor size
6. Accelerated chemotherapy given before surgery benefits patients with muscle-invasive bladder cancer
7. Breast MRI helps predict chemotherapys effectiveness
8. Why chemotherapy fails
9. Overexpression of proteins 14-3-3 related to chemotherapy resistance
10. Chemotherapy effective for patients with resected SCLC or large-cell neuroendocrine carcinoma
11. Pediatric regime of chemotherapy proves more effective for young adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... United Benefit Advisors ... the latest addition to its growing list of Partner Firms. S.S. Nesbitt ... from Orlando to Huntsville and in between. , Harnessing the experience and insights ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... time Emmy award winner and inspirational speaker Jan Fox will serve as keynote ... Speaking Boldly will provide participants with tools to more effectively communicate with their ...
(Date:2/10/2016)... Beach, Florida (PRWEB) , ... February 10, 2016 ... ... Country Club) announced that it has been awarded the prestigious Distinguished Emerald Club ... World award program conducted by BoardRoom magazine, one of the most respected trade ...
(Date:2/10/2016)... CA (PRWEB) , ... February 10, 2016 , ... Workrite ... and most versatile series of monitor mounts ever. , “Our goal was to ... and easy to install system that we have ever created.” said Darren Hulsey, Product ...
(Date:2/10/2016)... ... February 09, 2016 , ... A new leadership team for ... FHU President Joe Wiley made the announcement Monday night, Feb. 8, prior to the ... graduate of FHU and the creator of GO! Camp, has been named director. Gayle ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... New York , February 10, 2016 ... Growth, Trends and Forecast 2015 - 2023 ", reveals that ... rather slow growth from 2015 to 2023 owing to patent ... a meager CAGR of 1.30% during the forecast period, the ... to US$38.9 bn in 2023. --> Antibacterial Drugs ...
(Date:2/10/2016)... 10, 2016 Intouch Solutions, a leading marketing ... industry-wide trend regarding the evolution of digital sales ... efficiently deliver compelling sales presentations via tablets. After ... in 2015, Intouch uncovered that while most pharmaceutical ... DSAs, many are not using them effectively during ...
(Date:2/10/2016)... , Feb. 9, 2016 ... Drug Administration (FDA) met with its Arthritis ... proposed biosimilar of Johnson & Johnson,s Remicade ... be approved in the U.S. The Biologics ... physician groups - Alliance for Patient Access, ...
Breaking Medicine Technology: